Endo International plc - Ordinary Shares (ENDP) Company Bio
Endo International plc focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The company was founded in 1920 and is based in Dublin, Ireland.
ENDP Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Endo International plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Endo International plc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Endo International plc, consider:
9% of the company's capital comes from equity, which is greater than merely 3.46% of stocks in our cash flow based forecasting set.
Endo International plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 17. This value is greater than 97.99% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ENDP, try GSK, STAA, USPH, ENTA, and MD.
Endo International plc (NASDAQ: ENDP) today announced that it has changed the time of its previously announced conference call in an attempt to reduce conflicts with other earnings calls. The Company will now host a conference call and webcast on second-quarter 2020 financial results on August 6, 2020 at 7:00am EDT before the U.S. financial markets open. A press release with second-quarter 2020 financial results will be issued after the market closes on August 5, 2020.
New York, New York--(Newsfile Corp. - July 30, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Endo International plc ("Endo" or the "Company")(NASDAQ:ENDP) of the August 18, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you invested in Endo stock or options between August 8, 2017 and June 10, 2020 and would like ...